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Abstract. The Tumor Necrosis Factor is a key mediator in hepatic inflammatory 
response during acute exposure to xenobiotics. The cellular effects of TNF are mediated via 
two cell surface receptors, TNF receptor 1 and TNF receptor 2. The purpose of this study was 
to examine the expression and to identify the cellular localization of TNFR2 in hepatic tissue 
by immunohistochemistry after systemic administration of the SWCNT. In the same time the 
cellular infiltration and the weight of the liver was correlated with the TNF alpha receptor 2 
expression. Mice were exposed intraperitoneally (ip) to either vehicle, phosphate-buffered 
saline (PBS), or SWCNT-DNA (1.5ml, 2.925 mg/kg) for 48 h. The hepatic response 
associated with SWCNT systemic administration was characterized by increased expression 
of the TNF receptor II especially in the hepatocytes from the centrilobular and midzonal areas 
of hepatic lobule. This induced elevation of the TNF receptor II is not followed by hepatic 
necrosis, inflammatory infiltration or significant changes in liver weight. 
  




The Tumor Necrosis Factor (TNF) is a pleiotropic, potent proinflammatory cytokine 
that induces cellular responses such as proliferation, production of inflammatory mediators, 
and cell death. In conjunction with interleukin 6 (IL6) TNF regulates the acute-phase 
response, adhesion molecule activation, and expression of the antioxidant genes, being 
perhaps the most critical and important mediator of cellular injury, inflammation, cell death, 
apoptosis, and tissue healing process (1). TNF is released primarily from stimulated 
macrophages, lymphoid cells, mast cells, endothelial cells, fibroblasts, and neuronal cells 
(17), being a key mediator in hepatic inflammatory response during acute chemical exposure. 
The induction of toxic effects and inflammation on the liver tissues depends on specific 
TNFR signaling, intimately the molecular response and the role of TNFα in regulating hepatic 
inflammatory cytokine and receptors and apoptotic gene expression being unique for various 
xenobiotics (14, 9).  
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The cellular effects of TNF are mediated via two cell surface receptors, p55 (TNFα 
receptor type I, CD120a, TNFRSF1a) and p75 (TNFα receptor type II, CD120b, TNFRSF1b), 
a 55 kD and 70-80 kD glycoproteins with a single membrane spanning hydrophobic segment. 
These two receptors are structurally related, but functionally distinct and are coexpressed on 
the surface of most cells, although in different amounts (8). TNFα receptor type I is rather 
constitutively expressed on a broad spectrum of different cell types and has been shown to 
mediate most of the known biologic effects of TNF. In contrast, expression of TNFα receptor 
type II seems to be modulated by various stimuli, having an increased expression in the some 
tumoral cells after treatment, after IL-1b or biomechanical stimulation, hypoxia or in the cases 
of rejection of the tissues after organ transplant (3,5). The interaction between these two 
receptors is complex; both are additionally proteolytically released as soluble molecules 
capable of binding TNF, being possible that the ratio TNFR1/TNFR2 could control TNF-a 
responses under inflammatory conditions (7, 17).  
The receptor II of the TNF is supposed to have an antiapoptotic role, acting through 
the nuclear factor kappa B (NF-KB) pathway, and also initiates cell survival by induction of 
antiapoptotic molecules and inhibition of proapoptotic proteins (cIAP-1/clAP-2) (10, 13). 
We previously shown that SWCNT are rapidly accumulating in the liver after 
systemic administration, and also that the administration of these molecules is correlated with 
the   increased expression of the oxidative stress markers (6, 12).  One of the known pathway 
of the CNT toxicity is linked to the oxidative processes, the activation of the TNF expression 
being a possible mediator of the CNT pathogenesis since this molecule mediates the toxicity 
of many xenobiotics with metabolic pro oxidative effects. The studies of Hatice et al. prove 
that the oxidative damage on the cells structures is mediated by TNFα, since oxidative stress 
promotes TNFR receptor self-interaction and ligand-independent and enhanced ligand-
dependent TNF signaling (2). 
 
MATERIALS AND METHODS 
 
The synthesis and the functionalisation technique of the SWCNT used in this 
experiment follow the protocol previously described by Simon et al. (11).  
 The experimental animal model was represented by 24 young male albino rats (Wistar 
strain) divided in two equal lots (SWCNT group and reference group). The SWCNT 
administration was done intraperitoneally in a volume of 1.5 ml per animal (SWCNT 
concentration of the solution was 390 mg/L). The reference lot was injected intraperitoneally 
with the vehicle saline solution (1.5 ml PBS). The animals were sacrificed at 48 hours from 
the administration point of the solutions. The detailed necropsy examination of the animals 
was followed by the measurement of the weight of the body and the measurement of the 
weight of the liver (absolute/relative). The measurement and gathering of the tissue samples 
was carried out following the recommendation of the INHAND (International Harmonization 
of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice).  
Histology 
The necropsy specimens were fixed in 10% neutral buffered formalin, embedded in 
paraffin, sectioned at 5-7 µm with a microtome Leica RM 2125 RT, and stained routinely by 
Hematoxylin-Eosin (HE) method. The slides were examined under a microscope Olympus 
BX 51 and the images were taken with Olympus SP 350 digital camera and processed by a 
special acquisition and image processing program, Olympus Cell B. 
Immunohistochemistry 
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The immunohistochemistry was performed on 5-7 µm using a polyclonal rabbit anti-
rat and human TNF receptor II (abcam ab15563) as primary antibody, following a protocol 
previously described by Hoffman et al. (4). For the detection we used the LSAB 
system(LSAB+System HRP-DakoCytomation, K0679). The secondary antibodies, biotin 
polyvalent, streptavidine-HRP, sub layer DAB+, cromogene DAB+ and hematoxiline Meyer 
were included in the LSAB kit.   
Quantification of the lesions and TNFα receptor II expression    
The quantification and grading of the expression of the TNF alpha receptor II was 
achieved following the protocol previously described by Hoffmann et al. (4). The 
quantification was carried  out visually within 10 high power field/slide at the 40x objective 
amplification, following the next semi quantitative scale: -score 0 (“basically no staining”)  
was given for positive immunohistochemical  staining for  less than 5% of the cells;  -score 1 
for 5–25% (“weak”)  immunohistochemical  positive staining; -score 2 (“moderate”) for 26–
50% positive staining and score 3 (“strong”) for more than 50% positive staining. Mean 
values were calculated and used for comparison of the different expression of the TNFα 
receptor 2. 
The extent of hepatic inflammatory cellular infiltration was examined following the 
gradation protocol previously described by Horn et all (14). The quantification was carried  
out within 10 high power field/slide at the 20x objective amplification, following the next 
scale: grade 0, no inflammatory cell influx; 1 no more than 1–3 cells/field; 2, few 
inflammatory cells (3 to5 cells/field); 3, moderate inflammatory cell infiltration (5 to15 
cells/field); 4, marked inflammatory cell infiltration (greater than 15 cells/field); and 5, severe 
inflammatory cell infiltration(more than 15 cells/field). 
 
RESULTS AND DISCUSSIONS 
 
The hepatic tissue from the vehicle group (classified as PBS group) contained no or 
only weak TNFR2 positive staining, localized randomly within hepatic lobules, with a slide 
preference to the hepatocytes from the periportal areas.   
 
  
Fig.1. Liver, SWCNT group,  
immunohistochemical expression of the 
TNFR2, moderate expression (26–50% of 
the hepatocytes); Ob x20 
Fig.2. Liver, SWCNT group, 
immunohistochemical expression of the 
TNFR2, high expression (more than 50% of 
the hepatocytes). Obx20 
Negative controls of the immunohistochemical staining by replacing the primary 
antibody with irrelevant IgG did not demonstrate positive staining (fig. 4). 
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The mean of the hepatic TNFR2- positive staining was significantly higher in the liver 
samples from the SWCNT group. A significant up regulation of TNFR2 was noticed 
especially in the hepatocytes from the centrilobular and midzonal areas of the hepatic lobules 
compared to PBS group samples. In the SWCNT group, the TNFR2 staining was restricted to 
the hepatocytes and to the few inflammatory cells found within the lobules. The endothelial 
cells of the arteries and veins stained poorly positive for TNFR2 (fig. 1, 2 and 3).  
This elevation of the TNF receptor II expression is not followed by, inflammatory 
infiltration or significant changes in liver weight, the values found in the PBS and SWCNT 
group having little differences.    
The hepatocytes reaction is intense for the TNF alfa, the receptor II can be the follow 
up of the oxidative stress induced by the nanotubes on a hepatic level. The TNFR2 pathway of 
TNF cytokine promotes either in cooperation with or independently of TNFR1, cell 
proliferation and cell survival (15).  
 
Experimental Group Liver weight Inflammatory 
infiltrate 
TNFRII expression 
PBS Group 6.93±0.47 0.41 1.666 
SWCNT Group 7.34±0.24 0.58 2.416 
 
  
Fig. 3. Liver, PBS group, 
immunohistochemical expresion of the 
TNFR2, low expression (5–25% of the 
hepatocytes). Obx10 
Fig. 4. Negative controls of the 
immunohistochemical staining. Lack of the 
signal for the TNF receptor II. Obx20 
 
  The contact between the hepatic cellular elements and single-walled carbon nanotubes 
does not induce the installment of a noticeable inflammatory response through the classical 
histological or cytological techniques at 48 hours from the administration of the SWCNT 
solution. This thing is due to the possible toxic mechanism of the carbon nanotubes that has as 
characteristic the late inflammatory response, the main histological alterations mentioned also 
in the field literatures being the proliferative inflammations, with a chronic character, around 
the accumulating areas of the nanotubes (18). 
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The absence of the inflammatory cell reaction and the hepatic tissue necrosis prior to 
the systemic administration and SWCNT accumulation denotes the lack of the significant 
acute hepatic toxicity. The same tissue response at the intraperitoneal administration of the 
nanotubes is found also by Pantarotto and Wang (16), authors which use the same 
administration path of SWCNT. 
CONCLUSIONS 
 
The hepatic response associated with SWCNT administration is characterized by 
increased expression of the TNF receptor II especially in the hepatocytes from the 
centrilobular and midzonal areas of the hepatic lobules. This elevation of the TNF receptor II 





The authors acknowledge grant support from the Romanian Ministry of Research 




1. Edwards, C. K., Borcherding, S. M., Zhang, J., and Borcherding, D. R. (1994). Role of 
tumor necrosis factor a in acute and chronic inflammatory responses: novel therapeutic 
approaches. In Xenobiotics and Inflammation (L. B. Schook, and D. L. Laskin, Eds.), pp. 
97–147. Academic Press, Boca Raton. 
2. Hatice Z. Ozsoy, Natarajan Sivasubramanian, Eric D. Wieder, Steen Pedersen, and 
Douglas L. Mann, 2008,  Oxidative Stress Promotes Ligand independent and Enhanced 
Ligand-dependent Tumor  Necrosis Factor Receptor Signaling, The Journal of Biological 
Chemestry. 
3. Hehlgans Thomas, Carola Seitz, Claire Lewis, and Daniela N. Mannel, 2001, Hypoxic 
Upregulation of TNF Receptor Type 2 Expression Involves NF-IL-6 and Is Independent 
of HIF-1 or HIF-2, Journal of Interferon and Cytokine Research 21:757–762. 
4. Hoffmann U., T. Bergler, M. Rihm, C. Pace, B. Kruger, P. Ru¨mmele, B. Stoelcker, B. 
Banas, D. N. Mannel and B. K. Kramer, 2009,  Upregulation of TNF Receptor Type 2 in 
Human and Experimental Renal Allograft Rejection, American Journal of 
Transplantation,  9: 675–686 Wiley Periodicals Inc. 
5. Mizuno T., Y. Goto, K. Baba, K. Masuda, K. Ohno, H. Tsujimoto, 2003, Molecular 
cloning of feline tumour necrosis factor receptor type I (TNFR I) and expression of TNFR 
I and TNFR II in lymphoid cells in cats, European Journal of Immunogenetics, 30(2), 107-
113. 
6. Mocan Teodora, Clichici Simona, Biris Alexandru Radu, Simon Stefania, Daicoviciu 
Doina, Tabaran Flaviu, Agoston-Coldea Lucia, Moldovan Remus, Mocan Lucian, 
Muresan Adriana, 2010, Effects of Subcutaneous Administration of DNA-Functionalized 
SWCNT Solutions Upon The Pattern of Oxidative Stress Generation, International PhD 
Conference, Faculty of Medicine, University of Szeged . 
7. Peschon Jacques J., Dauphine S. Torrance, Kim L. Stocking, Moira B. Glaccum, Carol 
Otten, Cynthia R. Willis, Keith Charrier, Philip J. Morrissey, Carol B. Ware and Kendall 
M. Mohle, 1998,  TNF Receptor-Deficient Mice Reveal Divergent Roles for p55 and p75 
in Several Models of Inflammation, Journal of Immunology, 160(2), 943-952. 
 375 
8. Renu A. Heller and Martin Kronke, 1994, Tumor Necrosis Factor Receptor-mediated 
Signaling Pathways, The Journal of Cell Biology, 126. 
9. Robert F. Schawbe and David A. Brenner, 2006,Mechanisms of Hepatic Toxicity I. TNF 
alpha-induced liver injury: role of IKK, JNK and ROS pathways,  American Journal of 
Phisiology. Gastrointestinal And Liver Physiology, 290. 
10. Rothe M, Pan MG, Henzel W J, Ayres TM, Goeddel DV., 1995, The TNFR2- TRAF 
signaling complex contains two novel proteins related to baculoviral inhibition of 
apoptosis proteins. Cell 1995;8:1243- 1252. 18.  
11. Simon S., A.R. Biris, D.M. Lupu, I. Misan, S. Clichici, T. Mocan and A.S. Biris, 2009, 
Duspersion of Carbon Nanotubes by Single-Strand DNA Wrapping for Advanced 
Biomadical Application , Journal of Physics: Conference Series, 182, 012079. 
12. Tabaran Flaviu, C. Catoi, Simona Clichici, Teodora Mocanu, A. Biris, Simon Stefania, A. 
Nagy, P. Bolfa, The Identification and Characterization of f-SWCNT from Tissue 
Samples by Confocal Laser Scanning Microscopy, Vol 67(1), pag. 324, Bulletin of 
University of Agricultural Science and Veterinary Medicine Cluj-Napoca. 
13. Taraglia L.A., Weber RF, Figari IS, Reynolds C, Polladino MA, Goeddel DV. The two 
different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl 
Acad Sci U S Am1991;88:9292-9296. 
14. Thomas L. Horn, Timothy D. O’Brien, Lawrence B. Schook, and Mark S., 2000, 
Rutherford,  Acute Hepatotoxicant Exposure Induces TNFR-Mediated Hepatic Injury and 
Cytokine/Apoptotic Gene Expression, TOXICOLOGICAL SCIENCES 54, 262–273.   
15. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. 
Tumor necrosis factor receptor and Fas signaling mechanisms. Ann Rev Immunol 
1999;17:331-367. 
16. Wang H.F., J.Wang, X.Y. Deng, H.F. Sun, Z.J. Shi, Z.N. Gu, Y.F. Liu, Y.L. Zhao, 2004  
Biodistribution of carbon single-wall carbon nanotubes in mice, J. Nanosci. Nanotechnol. 
4 1019–1024. 
17. Weiss T., M. Grell, B. Hessabi, S. Bourteele, G. Muller, P. Scheurich, and H. Wajant. 
1997. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80. J. 
Immunol. 158:2398. 
18. Wing-Chiu Lam,  John T. James, Richard McCluskey, Robert L. Hunter, 2003, Pulmonary 
Toxicity of Single-Wall Carbon Nanotubes in Mice 7 and 90 Days After Intratracheal 
Instillation, Nanotoxicology. 
